278 related articles for article (PubMed ID: 27418444)
41. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
[TBL] [Abstract][Full Text] [Related]
42. Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial.
Harper M; Thom E; Klebanoff MA; Thorp J; Sorokin Y; Varner MW; Wapner RJ; Caritis SN; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM; Anderson GD;
Obstet Gynecol; 2010 Feb; 115(2 Pt 1):234-242. PubMed ID: 20093894
[TBL] [Abstract][Full Text] [Related]
43. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.
Gyamfi C; Horton AL; Momirova V; Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Meis PJ; Spong CY; Dombrowski M; Sibai B; Varner MW; Iams JD; Mercer BM; Carpenter MW; Lo J; Ramin SM; O'Sullivan MJ; Miodovnik M; Conway D;
Am J Obstet Gynecol; 2009 Oct; 201(4):392.e1-5. PubMed ID: 19716543
[TBL] [Abstract][Full Text] [Related]
44. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
Facchinetti F; Vergani P; Di Tommaso M; Marozio L; Acaia B; Vicini R; Pignatti L; Locatelli A; Spitaleri M; Benedetto C; Zaina B; DʼAmico R
Obstet Gynecol; 2017 Jul; 130(1):64-70. PubMed ID: 28594783
[TBL] [Abstract][Full Text] [Related]
45. Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate.
;
Am J Obstet Gynecol; 2023 Jul; 229(1):B2-B6. PubMed ID: 37061078
[TBL] [Abstract][Full Text] [Related]
46. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
Co AL; Walker HC; Hade EM; Iams JD
Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
[TBL] [Abstract][Full Text] [Related]
47. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
[TBL] [Abstract][Full Text] [Related]
48. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
Gupta S; Roman AS
Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
[TBL] [Abstract][Full Text] [Related]
49. A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
Frey HA; Finneran MM; Hade EM; Waickman C; Lynch CD; Iams JD; Landon MB
Am J Perinatol; 2023 Nov; 40(15):1695-1703. PubMed ID: 34905780
[TBL] [Abstract][Full Text] [Related]
50. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
Hines M; Lyseng-Williamson KA; Deeks ED
Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
[TBL] [Abstract][Full Text] [Related]
51. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
Stetson B; Hibbard JU; Wilkins I; Leftwich H
Obstet Gynecol; 2016 Nov; 128(5):983-988. PubMed ID: 27741201
[TBL] [Abstract][Full Text] [Related]
52. Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm Birth.
Manuck TA; Smeester L; Martin EM; Tomlinson MS; Smith C; Varner MW; Fry RC
Am J Perinatol; 2018 Jul; 35(8):721-728. PubMed ID: 29241278
[TBL] [Abstract][Full Text] [Related]
53. Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate.
Szychowski JM; Berghella V; Owen J; Hankins G; Iams JD; Sheffield JS; Perez-Delboy A; Wing DA; Guzman ER;
J Matern Fetal Neonatal Med; 2012 Dec; 25(12):2686-9. PubMed ID: 22889234
[TBL] [Abstract][Full Text] [Related]
54. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
[TBL] [Abstract][Full Text] [Related]
55. Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth.
Kalata M; Teter K; Wagner L; Swarr V; Witzeman K
J Matern Fetal Neonatal Med; 2021 Feb; 34(4):541-546. PubMed ID: 31006296
[No Abstract] [Full Text] [Related]
56. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
Feghali M; Venkataramanan R; Caritis S
Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193
[TBL] [Abstract][Full Text] [Related]
57. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Saha PT; Mbewe FM; Phiri WM; Peterson M; Muyangwa D; Sindano N; Mwape H; Smithmyer ME; Kasaro MP; Rouse DJ; Goldenberg RL; Chomba E; Stringer JSA
Lancet HIV; 2021 Oct; 8(10):e605-e613. PubMed ID: 34509197
[TBL] [Abstract][Full Text] [Related]
58. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Mulenga HB; Winston J; Mbewe FM; Chomba E; Mofenson LM; Rouse DJ; Goldenberg RL; Stringer JSA
BMC Pregnancy Childbirth; 2019 Feb; 19(1):81. PubMed ID: 30813934
[TBL] [Abstract][Full Text] [Related]
59. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
Heyborne KD; Allshouse AA; Carey JC
Am J Obstet Gynecol; 2015 Dec; 213(6):844.e1-6. PubMed ID: 26275354
[TBL] [Abstract][Full Text] [Related]
60. Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
Alizadeh F; Mahmoudinia M; Mirteimoori M; Pourali L; Niroumand S
BMC Pregnancy Childbirth; 2022 Mar; 22(1):167. PubMed ID: 35232423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]